Every 8-K that Neuronetics, Inc. (STIM) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow STIM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full STIM filings page.
Neuronetics, Inc. announced a leadership transition in its finance function. On August 11, 2026, Francis X. Brown III’s service as the company’s interim principal financial and accounting officer ended; the company states this change is not due to any dispute or disagreement with him regarding operations, policies, or practices, and he will continue as a consultant. The Board had previously appointed Nir Naor as Executive Vice President, Chief Financial Officer, and Treasurer effective July 23, 2026, and on August 12, 2026, expanded his responsibilities by designating him as principal financial and accounting officer and Corporate Secretary. Neuronetics notes that Mr. Naor received no additional compensation in connection with these expanded roles, discloses that there are no family relationships or arrangements underlying his selection, and states there are no related party transactions requiring disclosure under Regulation S-K Item 404(a).
Neuronetics, Inc. reported improved second-quarter 2026 results, driven by its Greenbrook clinic network. Total revenue for the three months ended June 30, 2026 was $41.6 million, up 9.1% from $38.1 million a year earlier. Greenbrook revenue rose to $26.9 million, up 16.8%, while NeuroStar revenue declined 2.7% to $14.7 million.
Gross margin expanded from 46.6% to 51.1%, reflecting a new go-to-market strategy and better revenue cycle management at Greenbrook. Operating expenses fell 12% to $22.7 million, reducing loss from operations to $1.5 million from $8.1 million. Adjusted EBITDA turned positive at $0.3 million versus a $5.6 million loss. Net loss narrowed to $3.4 million, or $0.05 per share, from $10.1 million, or $0.15 per share.
As of June 30, 2026, total cash (cash and cash equivalents plus restricted cash) was $25.0 million, down from $34.1 million at December 31, 2025, and long-term debt was $61.5 million. For full-year 2026, the company expects revenue of $160–$164 million (7–10% growth), gross margin between 48% and 50%, operating expenses of $91–$96 million excluding about $4 million of stock-based compensation, and cash flow from operations and investing between $(10.5) million and $(14.5) million.
Neuronetics, Inc. announced executive leadership changes and related compensation arrangements. The Board appointed Nir Naor as Executive Vice President, Chief Financial Officer, and Treasurer, effective on or about July 23, 2026, under an offer letter providing a $480,000 base salary, a target annual bonus equal to 50% of base salary, and a grant of 500,000 Restricted Stock Units vesting over four years. If terminated without cause or if he resigns for good reason, he is entitled to 12 months of base salary, a prorated target bonus, and continued health coverage. The company also reported that W. Andrew Macan, Executive Vice President, Chief Legal Officer, and Corporate Secretary, will depart on August 15, 2026, receiving a retention bonus of $231,750, vesting of 164,361 RSUs, and a separation payment of $475,087.50 paid over 12 months; his departure is stated not to result from any dispute or disagreement.
Neuronetics, Inc. announced that its board of directors has promoted Cory Anderson to Executive Vice President, General Manager of Greenbrook, effective July 1, 2026. He moves from his prior role as Senior Vice President, Chief Technology Officer and brings over 25 years of medical device leadership experience.
In connection with the promotion, Anderson’s annual base salary will increase to $425,000, and his target discretionary annual cash bonus will be set at 45% of his then-current base salary. He will remain eligible for annual equity grants under the company’s long‑term incentive program and continues under existing indemnification, restrictive covenant, and severance agreements.
Neuronetics, Inc. reported the voting results from its Annual Meeting of Stockholders. A total of 55,950,118 shares of common stock, representing approximately 80.41% of shares outstanding and eligible to vote, were present in person or by proxy, establishing a quorum.
All seven director nominees were elected to one-year terms with individual support levels ranging from about 28.5 million to 34.5 million votes. Stockholders also ratified the appointment of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
On a non-binding advisory basis, stockholders approved executive compensation with 29,133,360 votes for and 11,503,294 against. They also approved the Neuronetics, Inc. 2026 Equity Incentive Plan, which received 23,802,955 votes for and 16,651,661 against, with additional abstentions and broker non-votes on both proposals.
Neuronetics, Inc. reported that it has updated the consulting arrangement with Francis X. Brown III, who serves as its Interim Principal Financial and Accounting Officer. Mr. Brown was previously engaged under an agreement dated April 22, 2026 and began serving as Interim PAO on May 5, 2026.
Under the new Amended and Restated Consulting Agreement dated May 18, 2026, his role is clarified to include ongoing service as Interim PAO until the company hires a full-time controller and a full-time principal financial and accounting officer or another written end date is agreed. His compensation is now set at $26,000 per month, replacing the earlier $25,000 fee for his interim services.
Neuronetics, Inc. reported first quarter 2026 revenue of $34.5M, up 8% from the same period in 2025, driven mainly by U.S. clinic revenue growth and higher NeuroStar system sales. U.S. clinic revenue rose to $21.5M, a 15% increase, while NeuroStar system revenue grew 13% to $3.2M. Treatment session revenue declined to $9.1M from $9.6M.
Gross margin slipped to 46.9% from 49.2%, but operating expenses fell 6% to $25.1M, narrowing the net loss to $(10.8)M, or $(0.16) per share. Adjusted EBITDA improved to $(6.6)M. Cash and restricted cash totaled $19.0M at March 31, 2026, down from $34.1M at year-end, reflecting a $5.0M debt repayment and operating cash use.
The company highlighted an Optum/UnitedHealthcare policy change allowing psychiatric mental health nurse practitioners to order and administer NeuroStar TMS in 26 states and Washington, D.C., expanding access to about 34.8 million covered lives. For full year 2026, Neuronetics expects revenue of $160–$166M with gross margin between 47–49% and cash flow from operations between $(13)M and $(17)M.
Neuronetics, Inc. announced several corporate updates, including leadership changes and a cost‑reduction initiative. Former President and CEO Keith J. Sullivan entered an Executive Consulting and Release Agreement and will provide consulting services through March 31, 2027 while continuing to vest in his existing equity awards.
The company initiated a workforce reduction affecting up to 5% of employees, expecting about $0.2 million in second‑quarter 2026 restructuring charges and annualized cost savings of roughly $2.5 million to $3.0 million, with most savings beginning in the third quarter of 2026. Executive Vice President, Chief Financial Officer, and Treasurer Steven E. Pfanstiel plans to resign effective May 1, 2026, and a search for his successor is underway.
Neuronetics also issued a press release reaffirming the financial guidance it provided during its fourth quarter 2025 earnings call, indicating that its revenue and expense expectations for fiscal 2026 remain unchanged despite these organizational changes.
Neuronetics, Inc. reported strong growth for Q4 and full-year 2025 alongside a leadership change. Q4 2025 revenue was $41.8 million, up 86% from Q4 2024, driven mainly by the Greenbrook clinic acquisition. Full-year 2025 revenue nearly doubled to $149.2 million from $74.9 million, with U.S. revenue up 101%.
Profitability remains a challenge: full-year gross margin fell to 48.5% from 72.3%, and net loss was $(39.1) million, an improvement from $(43.7) million. The company ended 2025 with $34.1 million in cash and restricted cash and generated $0.9 million of operating cash in Q4.
The board appointed Dan Reuvers as President and CEO effective March 23, 2026, with an initial base salary of $730,000 and a grant of 1.5 million RSUs. For 2026, Neuronetics guides to revenue of $160–$166 million, expects operating expenses of $100–$105 million, and anticipates significantly improved operating cash flow as efficiency initiatives and the Greenbrook integration progress.
Neuronetics, Inc. entered into a Second Amendment to its Registration Rights Agreement with Madryn Asset Management and its affiliates. The amendment updates how Neuronetics will handle potential future resale registrations of Neuronetics shares held by the Madryn parties and adds a voting commitment.
Under the amendment, if Neuronetics receives a Shelf Notice after the amendment becomes effective, it must prepare and file a registration statement for resale of all Registrable Securities then beneficially owned by the Madryn parties as promptly as practicable and within five business days after filing its Form 10‑K for the year ended December 31, 2025. The Madryn parties also agree to vote all Neuronetics shares they own at the 2026 annual meeting in line with the Board of Directors’ voting recommendations on certain proposals defined in the amendment.
Neuronetics, Inc. reported that its Board and Compensation Committee approved annual cash incentive awards for three senior executives. On February 23, 2026, the Compensation Committee approved cash incentives of $73,216.44 for Executive Vice President and Chief Financial Officer Steven E. Pfanstiel and $163,383.75 for Executive Vice President, Chief Legal Officer, and Corporate Secretary W. Andrew Macan.
On the same date, the Board, following the Compensation Committee’s recommendation, approved an annual cash incentive award of $412,775.95 for President and Chief Executive Officer Keith J. Sullivan. The company stated that these cash incentive awards will be paid on or about March 13, 2026.
Neuronetics, Inc. reported selected preliminary, unaudited results showing strong growth for the fourth quarter and full year 2025. Fourth quarter 2025 revenue was $41.8 million, up 23% on an adjusted pro‑forma basis and 86% versus reported fourth quarter 2024. NeuroStar revenue was $18.3 million, with 49 NeuroStar Advanced Therapy systems shipped, while clinic revenue reached $23.5 million, up 37% on an adjusted pro‑forma basis.
For full year 2025, revenue was $149.2 million, a 15% increase on an adjusted pro‑forma basis and 99% higher than reported 2024. Full year NeuroStar revenue was $62.2 million, and clinic revenue was $87.0 million, up 28% on an adjusted pro‑forma basis. The company generated positive operating cash flow of $0.9 million in the quarter and ended 2025 with $34.1 million in total cash.
Neuronetics, Inc. entered into Amendment No. 4 to its existing Credit Agreement and Guaranty with Perceptive Credit Holdings IV, LP and other lenders. This amendment changes how the company’s subsidiaries are required to join the credit facility as an “Obligor” and “Subsidiary Guarantor”, affecting which subsidiaries must guarantee the company’s debt under this agreement.
The amendment is part of the company’s ongoing relationship with Perceptive and adjusts the guarantee structure rather than creating a new financing arrangement. The full legal terms are contained in the amendment, which is filed as an exhibit to this report.
Neuronetics, Inc. reported that its Compensation Committee approved new cash and restricted stock unit awards for two senior executives. Steven E. Pfanstiel, Executive Vice President, Chief Financial Officer and Treasurer, received a cash award of $240,000 and 170,212 restricted stock units. W. Andrew Macan, Executive Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary, received a cash award of $231,750 and 164,361 restricted stock units. The cash awards will be paid and the RSUs will vest on the earlier of June 30, 2027 or a termination of employment without cause.
Neuronetics, Inc. (STIM) filed an 8-K announcing it furnished a press release with financial results for the three months ended September 30, 2025 (Exhibit 99.1) and an investor presentation (Exhibit 99.2). The materials are furnished, not filed, under the Exchange Act.
The company also disclosed a planned leadership transition: President & CEO Keith J. Sullivan intends to retire on June 30, 2026. A search for his successor has begun. He will continue in his role until a successor is appointed and then serve as a consultant to support a seamless transition. The company stated his decision was not due to any dispute or disagreement.
Neuronetics, Inc. (STIM) filed an 8-K on 5-Aug-2025 announcing Amendment No. 3 to its July 2024 Credit Agreement with Perceptive Credit Holdings IV.
- Immediate liquidity: the amendment allows the company to draw a $10 million Tranche 2A term loan on the execution date (1-Aug-2025).
- Covenant relief: the minimum cash/liquidity requirement is reduced to $2 million through 30-Sep-2026, giving the company additional flexibility.
- Equity sweetener: Perceptive receives a warrant for 225,000 common shares; exercise terms were not disclosed in the filing.
Items 2.02 and 7.01 merely furnish (not file) the company’s Q2-25 earnings press release (Ex. 99.1) and an investor presentation (Ex. 99.2); no financial figures are included in this document.
Exhibits disclosed are: 10.1 (Amendment), 99.1 (press release), 99.2 (presentation) and 104 (iXBRL cover).